Nearly 60 global healthcare companies have been impacted in some way by the efforts of state officials to obtain execution drug supplies, and where necessary have taken action to mitigate the risks associated with the diversion and misuse of their products in lethal injection executions:

  1. Abbott
  2. AbbVie
  3. Accord
  4. Actavis
  5. Akorn
  6. Alvogen
  7. Amgen
  8. Amerisource
  9. APP
  10. AstraZeneca
  11. Athenex
  12. AuroMedics
  13. Baxter
  14. B Braun
  15. BD Rx
  16. Cadila Healthcare
  17. Cardinal Health
  18. Celgene
  19. Centene
  20. Custopharm
  21. Daiichi Sankyo
  22. Eli Lilly
  23. Endo
  24. Emcure
  25. Fresenius Kabi
  26. Ganpati Exim
  27. Gland Pharma
  28. GlaxoSmithKline
  29. Henry Schein
  30. Hikma
  31. Heritage
  32. Hospira
  33. Intas
  34. Janssen
  35. Jiangsu Hengrui
  36. Johnson & Johnson
  37. Kayem
  38. Luitpold
  39. Lundbeck
  40. McKesson
  41. MedPharmex
  42. Mylan
  43. Naari
  44. Novartis
  45. Par
  46. Pfizer
  47. Purdue
  48. Renaissance
  49. Roche
  50. Sagent
  51. Sandoz
  52. Shrenik Pharma
  53. Sun Pharma
  54. Tamarang
  55. Teva
  56. Valeant
  57. X‐Gen
  58. Zydus